Ghezzi C, Fagret D, Arvieux C C, Mathieu J P, Bontron R, Pasqualini R, de Leiris J, Comet M
Equipe de Physiopathologie Cellulaire Cardiaque et Laboratoire d'Etude des Radiopharmaceutiques, Université Joseph Fourier, Grenoble, France.
J Nucl Med. 1995 Jun;36(6):1069-77.
[Bis (N-etoxy, N ethyl dithiocarbamato) nitrido] 99mTc (V) (TcN-NOET) is a new neutral lipophilic myocardial imaging agent proposed for clinical use for detecting coronary artery disease. We studied the relation between myocardial retention of TcN-NOET and myocardial blood flow (MBF) in a canine model.
A wide range of MBF was induced by partial regional coronary occlusion and dipyridamole infusion (protocols 1,2 and 3). Myocardial activity of TcN-NOET was determined by in vitro tissue counting at 15 or 90 min postinjection. Tracer activity was correlated with radiolabeled microspheres using linear regression analysis.
There was a linear correlation between myocardial TcN-NOET activity and microspheres in protocol 1 (r = 094, 15 min postinjection, protocol 2 (r = 0.94, 15 min postinjection after dipyridamole) and protocol 3 (r = 0.91, 90 min postinjection after dipyridamole). When arterial occlusion was discontinued (protocol 4), there was no longer a close linear correlation (r = 0.26). The first-pass myocardial extraction action of TcN-NOET was 75.5% +/- 4% under basal conditions and 85% +/- 2% under hyperemic conditions (p < 0.01).
Up to 90 min after injection, the relationship between TcN-NOET myocardial retention and blood flow is excellent over a wide range of flows. After reflow, TcN-NOET redistributes almost completely within 90 min.
[双（N - 乙氧基，N - 乙基二硫代氨基甲酰基）亚硝酰基]锝99m（V）（TcN - NOET）是一种新的中性亲脂性心肌显像剂，被提议用于临床检测冠状动脉疾病。我们在犬模型中研究了TcN - NOET的心肌摄取与心肌血流（MBF）之间的关系。
通过局部区域冠状动脉闭塞和双嘧达莫输注（方案1、2和3）诱导出广泛范围的MBF。在注射后15或90分钟通过体外组织计数测定TcN - NOET的心肌活性。使用线性回归分析将示踪剂活性与放射性标记微球相关联。
在方案1中（注射后15分钟，r = 0.94）、方案2中（双嘧达莫后注射后15分钟，r = 0.94）和方案3中（双嘧达莫后注射后90分钟，r = 0.91），心肌TcN - NOET活性与微球之间存在线性相关性。当动脉闭塞解除时（方案4），不再有紧密的线性相关性（r = 0.26）。在基础条件下，TcN - NOET的首次通过心肌摄取率为75.5%±4%，在充血条件下为85%±2%（p < 0.01）。
注射后长达90分钟，在广泛的血流范围内，TcN - NOET心肌摄取与血流之间的关系良好。再灌注后，TcN - NOET在90分钟内几乎完全重新分布。
